229 related articles for article (PubMed ID: 22245905)
1. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
[TBL] [Abstract][Full Text] [Related]
2. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Tian M; Zhang X; Huang G; Fan W; Li J; Zhang Y
Abdom Radiol (NY); 2019 Oct; 44(10):3304-3311. PubMed ID: 31250181
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
4. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.
Memon K; Kulik L; Lewandowski RJ; Wang E; Riaz A; Ryu RK; Sato KT; Marshall K; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Senthilnathan S; Baker T; Gates VL; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
Gastroenterology; 2011 Aug; 141(2):526-35, 535.e1-2. PubMed ID: 21664356
[TBL] [Abstract][Full Text] [Related]
5. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
9. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Liu L; Zhao Y; Jia J; Chen H; Bai W; Yang M; Yin Z; He C; Zhang L; Guo W; Niu J; Yuan J; Cai H; Xia J; Fan D; Han G
Sci Rep; 2016 Feb; 6():19851. PubMed ID: 26831408
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
[TBL] [Abstract][Full Text] [Related]
12. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K
Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
[TBL] [Abstract][Full Text] [Related]
14. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.
Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Wu JC; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD
Clin Radiol; 2012 May; 67(5):429-36. PubMed ID: 22153231
[TBL] [Abstract][Full Text] [Related]
15. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
An C; Wei R; Yao W; Han W; Li W; Shi G; Wu P
Cancer Med; 2024 Jun; 13(11):e7319. PubMed ID: 38819606
[TBL] [Abstract][Full Text] [Related]
16. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.
Chan SL; Mo FK; Johnson PJ; Hui EP; Ma BB; Ho WM; Lam KC; Chan AT; Mok TS; Yeo W
J Clin Oncol; 2009 Jan; 27(3):446-52. PubMed ID: 19064965
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.
Riaz A; Gabr A; Abouchaleh N; Ali R; Al Asadi A; Mora R; Kulik L; Desai K; Thornburg B; Mouli S; Hickey R; Miller FH; Yaghmai V; Ganger D; Lewandowski RJ; Salem R
Hepatology; 2018 Mar; 67(3):873-883. PubMed ID: 28833344
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
19. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
[TBL] [Abstract][Full Text] [Related]
20. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Kudo M
J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]